EMERGENT BIOSOLUTIONS INC. (EBS)

Every figure this model derived for EBS, the value it took, and the element in the company's own XBRL it was read from — so any of it can be checked against the filing rather than taken on trust. As at 2026-06-30.

The figures, and where each came from

This is the part no other screener shows. Each figure below names the XBRL element it was read from, so it can be checked against the filing itself.

FigureValueXBRL tagAs at
capex 11,800,000 PaymentsToAcquirePropertyPlantAndEquipment 2026-06-30
cash 139,700,000 CashAndCashEquivalentsAtCarryingValue 2026-06-30
current assets 666,000,000 AssetsCurrent 2026-06-30
current liabilities 122,800,000 LiabilitiesCurrent 2026-06-30
equity 341,400,000 StockholdersEquity 2026-06-30
interest expense 50,900,000 InterestExpenseNonoperating 2026-06-30
ocf 97,700,000 NetCashProvidedByUsedInOperatingActivities 2026-06-30
revenue 770,200,000 RevenueFromContractWithCustomerExcludingAssessedTax 2026-06-30
sbc 18,900,000 ShareBasedCompensation 2026-06-30

The ratios

The figures themselves rather than their scores — what somebody looking up EBS on one particular measure came for.

RatioValue
cash operating margin27.71
current ratio6.18
current ratio reported5.42
deferred revenue growth206.12
dilution pct6.99
fcf margin11.15
interest cover1.97
net debt ebitda2.31
operating margin13.0
owner earnings margin8.7
revenue growth-9.56
revenue growth per share-15.46
roic9.99
rpo growth-9.5
rule of 403.44
sbc pct revenue2.45

What to be careful about

What this model itself distrusts about EBS's figures. Written by the derivation as it ran, not added afterwards.